TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
13.9.2022 15:02:00 EEST | Business Wire | Press release
Abiomed (Nasdaq: ABMD) will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab and operating room at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference, held in Boston from September 16 to 19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005521/en/
Impella 5.5 with SmartAssist delivers full cardiac support with maximum unloading, allowing the heart to rest and recover. (Graphic: Business Wire)
During the conference, physician-researchers will present clinical data demonstrating Impella leads to higher survival rates for cardiogenic shock patients and quality of life improvements for heart failure patients. Additional presentations and live cases will describe how Impella innovation and best practices have advanced safety and ease-of-use. Attendees can also receive hands-on Impella training and learn about future Impella technology.
Clinical Data Presentations:
Impella will be featured in presentations on topics that include a new analysis of data from the STEMI-DTU pilot randomized controlled trial and new data on cardiogenic shock and myocarditis outcomes from the J-PVAD registry in Japan. The J-PVAD registry is overseen by 10 Japanese professional societies, including the Japanese Circulation Society.
Abiomed’s preCARDIA technology to treat acute decompensated heart failure (ADHF) will be featured in two presentations that provide data showing preCARDIA reduces stressed blood volume and improves urine sodium excretion in ADHF patients.
Additionally, Abiomed will host two symposia with physician-researchers discussing the benefits of Impella as a therapy for patients in cardiogenic shock and Impella-supported high-risk PCI. They are:
- From Shock Spiral to Survival: Achieving Heart Recovery in Cardiogenic Shock – This in-person symposium takes place on Saturday, September 17, from 12:45–1:45 pm EDT in the TCT Presentation Theatre. Navin K. Kapur, MD, Tufts Medical Center, Boston; Katherine Kunkel, MD, Piedmont Heart Institute, Atlanta; Junya Ako, MD, Kitasato University Hospital, Tokyo; and Jay Giri, MD, MPH, Penn Medicine, Philadelphia, will present on best practices for Impella use to improve cardiogenic shock survival. A panel discussion will take place that will also include William O’Neill, MD and Mir Babar Basir, DO, from Henry Ford Hospital, Detroit.
- The CAD’s Out of the Bag: Achieving Heart Recovery in High-Risk Revascularization – This symposium is in-person and will be live streamed from the TCT World Connect Theatre on Sunday, September 18, from 12:30–1:30 pm EDT. Jonathan Hill, MD, Royal Brompton and Harefield Hospital, London; and Kate Kearney, MD, University of Washington, Seattle, will discuss clinical trials and best practices for Impella-supported high-risk PCI. Additionally, Navin K. Kapur, MD, Tufts Medical Center, Boston, will discuss ventricular unloading and what can be learned from the STEMI-DTU randomized controlled trial. A panel discussion will take place that will also include Gregg Stone, MD, Mount Sinai Health System, New York; Amir Kaki, MD, Ascension St. John Hospital, Detroit; and Cindy Grines, MD, Northside Hospital, Atlanta.
A detailed agenda for each symposium is available at this link on the TCT website.
Technology and Training:
Physicians attending the conference can receive hands-on Impella best practice training in the TCT Training Pavilion on topics such as access and closure, Impella RP with SmartAssist insertion and advanced Impella management. The esteemed faculty teaching these courses are Rajiv Tayal, MD, Valley Health System, Ridgewood, NJ; Robert Salazar, MD, Memorial Hermann, Houston; and Dan Burkhoff, MD, PhD, Cardiovascular Research Foundation. A detailed agenda for each training is available at this link on the TCT website.
Conference attendees are invited to visit the Abiomed booth, in the TCT Exhibit Hall. Abiomed’s booth will feature the latest Impella technology, including Impella 5.5 with SmartAssist and Impella RP with SmartAssist. Future pipeline technology will be available to preview, including Impella ECP, Impella RP Flex, Impella BTR and preCARDIA. Additionally, advanced Impella trainers will be available to answer questions about Impella’s new heparin-free purge, provide a hands-on experience with the Impella simulator and guide attendees through Abiomed’s new virtual reality training technology.
Live Daily Recap Program:
Abiomed’s TCT daily recap program will broadcast live from 6:00–6:30 pm EDT on Saturday, September 17 through Monday, September 19. The program will summarize the day’s news from TCT. It will be hosted by Abiomed’s chief medical officer, Chuck Simonton, MD, and Abiomed’s vice president for professional education and medical communication, Seth Bilazarian, MD. To watch live, log on to www.heartrecovery.com.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® with SmartAssist® are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.
Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD® and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
Impella RP® and Impella RP® with SmartAssist are U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http://www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005521/en/
Contact information
Media Contact:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com
Investor Contact:
Todd Trapp
Executive Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KILL IQM Named Among Quantum Collaborators in HPE's New Hybrid Quantum-HPC Platform23.6.2026 01:17:00 EEST | Press release
IQM Quantum Computersrequests that their press release NewsItemId: 20260622035759 “IQM Named Among Quantum Collaborators in HPE's New Hybrid Quantum-HPC Platform” be killed. The release was issued in error by IQM Quantum Computers. A replacement release will be issued at a later date.
One Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC Therapies22.6.2026 23:15:00 EEST | Press release
One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced financial support via a Paris-Saclay Cancer Cluster (PSCC) BOOST grant to develop the first single-cell assay for antibody-drug conjugates (ADC) therapies in oncology. The rapid growth of ADCs is driving demand for more sophisticated biomarker strategies. By capturing tumor complexity at cellular resolution, single-cell profiling has the potential to enhance patient selection and support the development of next-generation ADCs. Ultimately, it will help match the right patients to the right therapies, maximizing therapeutic benefit. The PSCC BOOST-funded project seeks to bring a new level of precision to ADC development. It will be conducted in collaboration with Adcytherix, a clinical-stage biotech company developing differentiated ADCs for cancers with high unmet medical need. The collaboration will combine Adcytherix’s expertise in ADC development with One Biosciences’ AI-powered
Interactive Brokers Expands AI Integration Capabilities – Adding ChatGPT and Grok to Its Growing Suite of Agentic Trading Tools22.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the expansion of its agentic trading capabilities with the addition of ChatGPT and Grok, further broadening a growing ecosystem of AI platform integrations that began with Claude. Available through certified AI connector marketplaces across multiple leading platforms, these integrations allow clients to research, analyze, and generate instructions with speed and efficiency to uncover new trading and investing opportunities instantly. With this release, Interactive Brokers also extends the selection of products available for order instructions to include support for options, futures and futures options in addition to equities and ETFs. “We continue to see growing interest from investors in using artificial intelligence as a more natural way to interact with financial markets,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “Adding ChatGPT and Grok, together with support for options and fut
IQM Named Among Quantum Collaborators in HPE's New Hybrid Quantum-HPC Platform22.6.2026 16:22:00 EEST | Press release
Hewlett Packard Enterprise has named IQM Quantum Computers among the companies collaborating on its hybrid classical-quantum computing platform, announced at HPE Discover Las Vegas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622035759/en/ IQM Radiance quantum computer at HPE Discover Las Vegas 2026 IQM, a global leader in full-stack superconducting quantum computers, is contributing superconducting quantum processor technology to the effort, in which HPE is integrating multiple quantum modalities with its Cray supercomputing infrastructure. This collaboration strengthens IQM's global expansion plans as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). For IQM, HPE's selection places the company at the center of one of the computing industry's most significant efforts to bring quantum and high-performance computing together, an integration widely rega
Return Abuse Goes Mainstream as Nearly Half of Consumers Use AI in Return Claims, New Riskified Research Finds22.6.2026 15:30:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today released a new global report, “Rewriting the Rules on Returns”, exploring how consumer attitudes and behaviors around ecommerce returns are evolving in the age of artificial intelligence (AI). The Riskified-commissioned study, conducted by eTail Insights, is based on a survey of 2,091 consumers across seven countries, alongside in-depth interviews with senior leaders from many of the largest retail companies in the world. The research finds that return abuse behaviors are increasingly normalized, while nearly half of consumers already use generative AI tools to assist with return or refund claims. At the same time, merchants are responding by tightening return policies, shortening return windows, and deploying advanced AI detection to better distinguish between legitimate behavior and abuse patterns. Key Findings Nearly half of consumers (50%) report using generative AI tools such as ChatG
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom